{"id":863,"date":"2021-03-01T05:30:18","date_gmt":"2021-03-01T05:30:18","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=863"},"modified":"2021-03-01T05:30:18","modified_gmt":"2021-03-01T05:30:18","slug":"19-feb-2021-ivermectin-days-to-covid-negativity-was-significantly-and-dose-dependently-reduced-by-iv","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/19-feb-2021-ivermectin-days-to-covid-negativity-was-significantly-and-dose-dependently-reduced-by-iv\/","title":{"rendered":"(19 Feb 2021) Ivermectin-Days to COVID negativity was significantly and dose dependently reduced by IV"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos<\/p>\n<p>https:\/\/doi.org\/10.1093\/qjmed\/hcab035<\/p>\n<p class=\"\">We conducted a translational proof of concept (PoC) randomized, double blind placebo controlled, dose response, parallel group study of IV efficacy in RT &#8211; PCR proven COVID 19 positive patients. 62 patients were randomized to 3 treatment groups. (A) IV 6mg regime, (B)IV 12 mg regime (given Q84hrs for 2weeks) (C, control) Lopinavir\/Ritonavir. All groups plus standard of Care. The Days to COVID negativity [DTN] was significantly and dose dependently reduced by IV (p = 0.0066). The DTN for Control were, = 9.1+\/-5.2, for A 6.0 +\/- 2.9, and for B 4.6 +\/-3.2 . 2 Way repeated measures ANOVA of ranked COVID 19 +\/- scores at 0, 84, 168, 232 hours showed a significant IV treatment effect (p = 0.035) and time effect (p &lt; 0.0001). IV also tended to increase SPO2% compared to controls, p = 0.073, 95% CI &#8211; 0.39 to 2.59 and increased platelet count compared to C (p = 0.037) 95%CI 5.55 &#8211; 162.55 x 103\/ml. The platelet count increase was inversely correlated to DTN (r = -0.52, p = 0.005). No SAE was reported.12 mg IV regime may have superior efficacy. IV should be considered for use in clinical management of SARS-Cov-2, and may find applications in community prophylaxis in high-risk areas.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos https:\/\/doi.org\/10.1093\/qjmed\/hcab035 We conducted a translational proof of concept (PoC) randomized, double blind placebo controlled, dose response, parallel group study of IV efficacy in&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/19-feb-2021-ivermectin-days-to-covid-negativity-was-significantly-and-dose-dependently-reduced-by-iv\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(19 Feb 2021) Ivermectin-Days to COVID negativity was significantly and dose dependently reduced by IV&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6,4,16],"tags":[38],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/863"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=863"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/863\/revisions"}],"predecessor-version":[{"id":864,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/863\/revisions\/864"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=863"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=863"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=863"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}